Why did INZY's EPS remain flat throughout 2024?


Aime
Inozyme Pharma's (INZY) EPS remained flat throughout 2024 due to a combination of factors:
- Consistent Financial Performance: The company maintained a consistent adjusted loss per share (EPS) throughout the year, with quarterly losses of -$1.62 per share as of December 31, 202412. This indicates a stable financial performance with no significant fluctuations in profitability.
INZY Diluted EPS YoY, Diluted EPS
- No Significant Changes in Revenue: The company's total revenue remained unchanged as of December 31, 20243. The absence of any notable increase in revenue suggests that the company's operational efficiency and market conditions were relatively consistent, which would have resulted in a stable EPS.
- Net Income and ROE Indicators: The net income for the company was -$102.02 million as of December 31, 20244, and the Return on Equity (ROE) was -102.9%5. These figures indicate that the company has been operating at a loss, which could be a result of high research and development costs, marketing expenses, or other operational costs that have not led to a corresponding increase in revenue.
1/2
INZY Net Income YoY, Net Income
- Analyst Estimates and Market Sentiment: Analysts have adjusted their EPS estimates for the company, with some raising their forecasts, as seen with Affinity Asset Advisors LLC and Dimensional Fund Advisors LP increasing their holdings67. However, the overall sentiment remains cautious, with a consensus rating of "Buy" and an average target price of $15.71, suggesting that while there is potential, it is balanced by the risks associated with the company's financial performance7.
In conclusion, Inozyme Pharma's EPS remained flat throughout 2024 due to a combination of consistent financial performance, no significant changes in revenue, and the company's operational and financial management strategies. The company's focus on maintaining financial stability despite operating at a loss is a key factor in the flat EPS trend.
Source:
1.
INZY EPS in 2024
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
Wiki